Second line of Avastin and Docetaxel beyond PD by CDDP/PEM/Ava+Ava/PEM for wild and unknown of EGFR/ ALK Non-SQ NSCLC
Phase 2
- Conditions
- wild and unknown of EGFR/ ALK Non-SQ NSCLC
- Registration Number
- JPRN-UMIN000009870
- Lead Sponsor
- niversity of Occupational and Environmental Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
They had a concurrent malignancy, symptomatic brain metastasis, uncontrollable complications, severe morbidity; hypersensitivity to therapeutic agents; bleeding; the possibility of being pregnant, and other conditions such as hepatic inflammation, as judged by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method RR for Second line of Bevacizumab and Docetaxel
- Secondary Outcome Measures
Name Time Method PFS, OS, DCR, RR forCDDP/PEM/Ava+Ava/PEM,DCR, safety